In a series of in vitro and in vivo studies, Zhao et al. showed that CLL-1 directed antibodies induced complement-dependent cytotoxicity against AML cell lines and primary cells, and furthermore reduced the tumor burden in AML xenograft mouse models [30]. Here, CLEC12A is linked to acute myeloid leukemia.